INVESTABOT
Equity Research
XNYS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Bristol-Myers Squibb generated $11.49B in Q1 2026 revenue, up 2.6% from $11.20B a year ago, while net income came in at $2.68B and GAAP EPS landed at $1.31.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/1/2026 | Gallman Cari | EVP, General Counsel | OPTION_EXERCISE | -1,061 | — | — |
| 8/1/2026 | Gallman Cari | EVP, General Counsel | TAX_WITHHOLD | -543 | $65 | $35,463 |
| 8/1/2026 | Gallman Cari | EVP, General Counsel | OPTION_EXERCISE | 1,061 | — | — |
| 8/1/2026 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | OPTION_EXERCISE | -51,172 | — | — |
| 8/1/2026 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | TAX_WITHHOLD | -26,175 | $65 | $1,709,489 |
| 8/1/2026 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | OPTION_EXERCISE | 51,172 | — | — |
| 6/30/2026 | Arduini Peter J | — | GRANT | 607.43 | $58 | $35,000 |
| 6/30/2026 | McMullen Michael R. | — | GRANT | 607.43 | $58 | $35,000 |
| 6/30/2026 | Rice Derica W | — | GRANT | 672.51 | $58 | $38,750 |
| 6/30/2026 | Samuels Theodore R. II | — | GRANT | 889.45 | $58 | $51,250 |
| 6/30/2026 | YALE PHYLLIS R | — | GRANT | 607.43 | $58 | $35,000 |
| 6/15/2026 | Haller Julia A | — | OPTION_EXERCISE | -20,460 | — | — |
| 6/15/2026 | Haller Julia A | — | OPTION_EXERCISE | 20,460 | $54 | $1,099,930 |
| 6/3/2026 | Short Bartie Wendy | EVP, Corporate Affairs | OPTION_EXERCISE | -8,040 | — | — |
| 6/3/2026 | Short Bartie Wendy | EVP, Corporate Affairs | TAX_WITHHOLD | -3,876 | $55 | $212,095 |
| 6/3/2026 | Short Bartie Wendy | EVP, Corporate Affairs | OPTION_EXERCISE | 8,040 | — | — |
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | OPTION_EXERCISE | 1,373 | — | — |
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | OTHER | -203 | — | — |
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | TAX_WITHHOLD | -599 | $58 | $34,874 |
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | OPTION_EXERCISE | -1,373 | — | — |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 198,727,768 | $10,719,375,805 | — | 1/29/2026 |
| BlackRock | 171,682,888 | $10,412,567,160 | -2.9% | 5/13/2026 |
| BlackRock | 180,384,994 | $10,393,783,402 | 5.1% | 8/7/2026 |
| BlackRock | 176,825,406 | $9,537,962,416 | — | 2/12/2026 |
| BlackRock | 158,658,853 | $6,589,102,184 | — | 8/13/2024 |
| State Street | 98,564,914 | $5,977,962,034 | 0.6% | 5/15/2026 |
| State Street | 102,408,940 | $5,900,803,123 | 3.9% | 8/7/2026 |
| JP Morgan Chase | 96,171,217 | $5,744,305,548 | 19.1% | 5/13/2026 |
| State Street | 97,980,438 | $5,285,064,826 | — | 2/13/2026 |
| JP Morgan Chase | 74,817,565 | $4,381,315,415 | -22.2% | 8/12/2026 |
| JP Morgan Chase | 80,716,176 | $4,353,829,442 | — | 2/11/2026 |
| AQR Capital | 29,631,105 | $1,797,126,523 | 14.9% | 5/15/2026 |
| Morgan Stanley | 29,198,673 | $1,770,892,561 | 3.0% | 5/15/2026 |
| Morgan Stanley | 29,009,144 | $1,671,500,302 | -0.7% | 8/13/2026 |
| AQR Capital | 27,357,486 | $1,576,338,331 | -7.7% | 8/14/2026 |
| Morgan Stanley | 28,348,756 | $1,529,125,717 | — | 5/27/2026 |
| AQR Capital | 25,796,905 | $1,391,485,051 | — | 2/17/2026 |
| Goldman Sachs | 18,893,877 | $1,019,135,745 | — | 3/25/2026 |
| Goldman Sachs | 17,427,999 | $1,004,201,340 | 19.7% | 8/14/2026 |
| Fidelity (FMR) | 16,293,303 | $938,820,087 | 52.7% | 8/13/2026 |